边缘供肝及器官功能维护在肝移植中的应用进展

戴清清; 赵红川; 王国斌; 黄帆

doi:10.3969/j.issn.1674-7445.2020.02.020

边缘供肝及器官功能维护在肝移植中的应用进展

doi: 10.3969/j.issn.1674-7445.2020.02.020

230022 合肥，安徽医科大学第一附属医院器官移植中心

基金项目:

安徽高校自然科学研究重点项目 KJ2017A193

详细信息

作者简介:
戴清清，男，1994年生，硕士研究生，研究方向为肝胆胰外科，Email：1650889787@qq.com

通讯作者:
赵红川，男，1969年生，博士，主任医师，研究方向为器官移植，Email：zhc0117@sina.com

中图分类号: R617
计量
- 文章访问数: 242
- HTML全文浏览量: 180
- PDF下载量: 19
- 被引次数: 0
出版历程
- 收稿日期: 2019-12-23
- 网络出版日期: 2021-01-19
- 刊出日期: 2020-03-15

Progress on application of marginal donor liver and organ function maintenance in liver transplantation

Organ Transplantation Center, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China

More Information

Corresponding author: Zhao Hongchuan, Email: zhc0117@sina.com

摘要

摘要: 肝移植是治疗各种终末期肝病的唯一有效方法。标准供肝短缺是限制肝移植发展的主要因素，而边缘供肝的使用明显扩大了供肝的来源。体外膜肺氧合（ECMO）、机械灌注及低体温等新型技术能显著改善边缘供肝的质量，在器官功能维护中具有良好的发展前景。本文就边缘供肝的常见类型及相关新型技术在边缘供肝功能维护中的应用展开综述。
- 肝移植 /
- 边缘供肝 /
- 器官功能维护 /
- 体外膜肺氧合(ECMO) /
- 机械灌注 /
- 低体温
Abstract: Liver transplantation is the only effective method to treat various end-stage liver diseases. The shortage of standard donor liver is the main factor limiting the development of liver transplantation, whereas the application of marginal donor liver has significantly expanded the source of donor liver. New technologies, such as extracorporeal membrane oxygenation (ECMO), mechanical perfusion and hypothermia, can significantly improve the quality of marginal donor liver, which has good development prospects in organ function maintenance. This article reviews the common types of marginal donor liver and the application of related novel technologies in the maintenance of marginal donor liver function.
- Liver transplantation /
- Marginal donor liver /
- Organ function maintenance /
- Extracorporeal membrane oxygenation (ECMO) /
- Mechanical perfusion /
- Hypothermia

HTML全文

参考文献(36)

[1]	VODKIN I. Extended criteria donors in liver transplantation[J]. Clin Liver Dis, 2017, 21(2):289-301. DOI: 10.1016/j.cld.2016.12.004.
[2]	JIMÉNEZ-GALANES S, MENEU-DIAZ MJ, ELOLA-OLASO AM, et al. Liver transplantation using uncontrolled non-heart-beating donors under normothermic extracorporeal membrane oxygenation[J]. Liver Transpl, 2009, 15(9):1110-1118. DOI: 10.1002/lt.21867.
[3]	D'ERRICO A, RIEFOLO M, SERENARI M, et al. The histological assessment of liver fibrosis in grafts from extended criteria donors predicts the outcome after liver transplantation: a retrospective study[J]. Dig Liver Dis, 2020, 52(2):185-189. DOI: 10.1016/j.dld.2019.05.013.
[4]	NAIR A. Extended criteria donors in liver transplantation-from marginality to mainstream[J]. Hepatobiliary Surg Nutr, 2018, 7(5):386-388. DOI: 10.21037/hbsn.2018.06.08.
[5]	BADAWY A, KAIDO T, UEMOTO S. Current status of liver transplantation using marginal grafts[J]. J Invest Surg, 2018, 20:1-12. DOI: 10.1080/08941939.2018.1517197.
[6]	TRAPERO-MARUGÁN M, LITTLE EC, BERENGUER M. Stretching the boundaries for liver transplant in the 21st century[J]. Lancet Gastroenterol Hepatol, 2018, 3(11):803-811. DOI: 10.1016/S2468-1253(18)30213-9.
[7]	PARK PJ, YU YD, YOON YI, et al. Single-center experience using marginal liver grafts in Korea[J]. Transplant Proc, 2018, 50(4):1147-1152. DOI: 10.1016/j.transproceed.2018.01.040.
[8]	GHINOLFI D, MARTI J, DE SIMONE P, et al. Use of octogenarian donors for liver transplantation: a survival analysis[J]. Am J Transplant, 2014, 14(9):2062-2071. DOI: 10.1111/ajt.12843.
[9]	LAKE JR, SHORR JS, STEFFEN BJ, et al. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis[J]. Am J Transplant, 2005, 5(3):549-557. DOI: 10.1111/j.1600-6143.2005.00741.x.
[10]	KIM DY, MOON J, ISLAND ER, et al. Liver transplantation using elderly donors: a risk factor analysis[J]. Clin Transplant, 2011, 25(2):270-276. DOI: 10.1111/j.1399-0012.2010.01222.x.
[11]	WU C, LU C, XU C. Short-term and long-term outcomes of liver transplantation using moderately and severely steatotic donor livers: a systematic review[J]. Medicine (Baltimore), 2018, 97(35):e12026. DOI: 10.1097/MD.0000000000012026.
[12]	POWNER DJ. Factors during donor care that may affect liver transplantation outcome[J]. Prog Transplant, 2004, 14(3):241-249. doi: 10.1177/152692480401400310
[13]	CYWINSKI JB, MASCHA E, MILLER C, et al. Association between donor-recipient serum sodium differences and orthotopic liver transplant graft function[J]. Liver Transpl, 2008, 14(1):59-65. DOI: 10.1002/lt.21305.
[14]	AKOAD M, WAGENER M, FRANCIS F, et al. Outcome of imported liver allografts and impact on patient access to liver transplantation[J]. Transplant Proc, 2006, 38(10):3564-3566. DOI: 10.1016/j.transproceed.2006.10.037.
[15]	MATHUR AK, HEIMBACH J, STEFFICK DE, et al. Donation after cardiac death liver transplantation: predictors of outcome[J]. Am J Transplant, 2010, 10(11):2512-2519. DOI: 10.1111/j.1600-6143.2010.03293.x.
[16]	NGUYEN JH, BONATTI H, DICKSON RC, et al. Long-term outcomes of donation after cardiac death liver allografts from a single center[J]. Clin Transplant, 2009, 23(2):168-173. DOI: 10.1111/j.1399-0012.2009.00968.x.
[17]	CRISMALE JF, KHALID M, BHANSALI A, et al. Liver, simultaneous liver-kidney, and kidney transplantation from hepatitis C-positive donors in hepatitis C negative recipients: a single center study[J]. Clin Transplant, 2019:e13761. DOI: 10.1111/ctr.13761.
[18]	WEI L, CHEN D, ZHANG B, et al. Long-term outcome and recurrence of hepatitis B virus following liver transplantation from hepatitis B surface antigen-positive donors in a Chinese population[J]. J Viral Hepat, 2018, 25(12):1576-1581. DOI: 10.1111/jvh.12972.
[19]	WONG TC, FUNG JY, CUI TY, et al. Liver transplantation using hepatitis B core positive grafts with antiviral monotherapy prophylaxis[J]. J Hepatol, 2019, 70(6):1114-1122. DOI: 10.1016/j.jhep.2019.03.003.
[20]	BAE SK, AKAMATSU N, TOGASHI J, et al. Hepatitis B virus recurrence after living donor liver transplantation of anti-HBc-positive grafts: a 22-year experience at a single center[J]. Biosci Trends, 2019, 13(5):448-455. DOI: 10.5582/bst.2019.01283.
[21]	LAI JC, O'LEARY JG, TROTTER JF, et al. Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study[J]. Liver Transpl, 2012, 18(5):532-538. DOI: 10.1002/lt.23396.
[22]	FENG S, BUELL JF, CHARI RS, et al. Tumors and transplantation: the 2003 third annual ASTS state-of-the-art winter symposium[J]. Am J Transplant, 2003, 3(12):1481-1487. doi: 10.1046/j.1600-6143.2003.00245.x
[23]	NALESNIK MA, WOODLE ES, DIMAIO JM, et al. Donor-transmitted malignancies in organ transplantation: assessment of clinical risk[J]. Am J Transplant, 2011, 11(6):1140-1147. DOI: 10.1111/j.1600-6143.2011.03565.x.
[24]	ASENI P, DE FEO TM, DE CARLIS L, et al. A prospective policy development to increase split-liver transplantation for 2 adult recipients: results of a 12-year multicenter collaborative study[J]. Ann Surg, 2014, 259(1):157-165. DOI: 10.1097.
[25]	VAGEFI PA, PAREKH J, ASCHER NL, et al. Outcomes with split liver transplantation in 106 recipients: the University of California, San Francisco, experience from 1993 to 2010[J]. Arch Surg, 2011, 146(9):1052-1059. DOI: 10.1001/archsurg.2011.218.
[26]	REDDY S, ZILVETTI M, BROCKMANN J, et al. Liver transplantation from non-heart-beating donors: current status and future prospects[J]. Liver Transpl, 2004, 10(10):1223-1232. DOI: 10.1002.
[27]	SAIDI RF. Utilization of expanded criteria donors in liver transplantation[J]. Int J Organ Transplant Med, 2013, 4(2):46-59. http://d.old.wanfangdata.com.cn/OAPaper/oai_doaj-articles_51eba3906b025a150d904fb7e2555d28
[28]	ASSALINO M, MAJNO P, TOSO C, et al. In situ liver splitting under extracorporeal membrane oxygenation in brain-dead donor[J]. Am J Transplant, 2018, 18(1):258-261. DOI: 10.1111/ajt.14461.
[29]	NASRALLA D, COUSSIOS CC, MERGENTAL H, et al. A randomized trial of normothermic preservation in liver transplantation[J]. Nature, 2018, 557(7703):50-56. DOI: 10.1038/s41586-018-0047-9.
[30]	BRUINSMA BG, YEH H, OZER S, et al. Subnormothermic machine perfusion for ex vivo preservation and recovery of the human liver for transplantation[J]. Am J Transplant, 2014, 14(6):1400-1409. DOI: 10.1111/ajt.12727.
[31]	SCHLEGEL A, MULLER X, KALISVAART M, et al. Outcomes of DCD liver transplantation using organs treated by hypothermic oxygenated perfusion before implantation[J]. J Hepatol, 2019, 70(1):50-57. DOI: 10.1016/j.jhep.2018.10.005.
[32]	GUARRERA JV, HENRY SD, SAMSTEIN B, et al. Hypothermic machine preservation facilitates successful transplantation of "orphan" extended criteria donor livers[J]. Am J Transplant, 2015, 15(1):161-169. DOI: 10.1111/ajt.12958.
[33]	MORITO N, OBARA H, MATSUNO N, et al. Regulated oxygenation of rewarming machine perfusion for porcine donation after cardiac death liver transplantation[J]. Transplant Proc, 2016, 48(4):1244-1246. DOI: 10.1016/j.transproceed.2015.12.098.
[34]	NIEMANN CU, FEINER J, SWAIN S, et al. Therapeutic hypothermia in deceased organ donors and kidney-graft function[J]. N Engl J Med, 2015, 373(5):405-414. DOI: 10.1056/NEJMoa1501969.
[35]	刘克普, 张更, 李智斌, 等.供体亚低温状态对公民逝世后器官捐献移植肾功能的影响[J].器官移植, 2017, 8(5):376-380.DOI: 10.3969/j.issn.1674-7445.2017.05.008. LIU KP, ZHANG G, LI ZB, et al. Effect of hypothermia status in donors on renal graft function after renal transplantation from donation after citizen's death[J]. Organ Transplant, 2017, 8(5): 376-380. DOI: 10.3969/j.issn.1674-7445.2017.05.008.
[36]	WRIGHT C, PATEL MS, GAO X, et al. The impact of therapeutic hypothermia used to treat anoxic brain injury after cardiopulmonary resuscitation on organ donation outcomes[J]. Ther Hypothermia Temp Manag, 2019, 9(4):258-264. DOI: 10.1089/ther.2018.0043.